Thyroid Disease in Pregnancy Josephine Carlos-Raboca, MD, FPCP, FPSEM Section of Endocrinology, Diabetes and Metabolism Makati Medical Center Outline Thyroid Physiology in Pregnancy Maternal Fetal Gestational Thyrotoxicosis Grave’s Disease in Pregnancy Hypothyroidism Postpartum thyroiditis H-P Thyroid Axis Maternal Physiology Thyroid circulation Thyroxine clearance rate Dietary iodine requirement hCG mediated thyroid stimulation Thryoxine binding globulin(TBG) Increased serum (TBG) due to estrogen induced sialylation of the protein which leads to decreased renal clearance and longer half life ( from normal 15 minutes, increased to 3 days) Effects of Increased TBG Increased total T3 and total T4 Free hormone assay are thus preferred FT4I should be done if free hormone determination is not available Thyroid Disposal/Clearance Iodinase Type 1 – liver, kidney, thyroid converts T4 to T3 Type 2 - pituitary, brown fat, brain converts T4 to T3 Type 3 – placenta brain and skin converts T4 to rT3 and T3 to T2 Increased demand for iodine Increased GFR Increased iodide clearance by the kidney Siphoning of maternal iodide by the fetus WHO: RDA 200 ug/day during pregnancy Increased demand for thyroid hormones Increased iodide clearance Transplacental transfer of T4 and iodine Placental degradation of T4 Thyroid stimulation by chorionic gonadotropin Similarity of TSH and HCG alpha subunit is common to TSH, hCG, FSH and LH Beta subunit is specific but some similarity in TSH and hCG HCG stimulates TSH receptor has weak thyrotropic activity 1/10000 of TSH Thyroid stimulation by hCG Physiologic changes in pregnancy and thyroid function test Physiologic change Increased TBG First trimester hCG elevation Increased plasma volume Increased plasma type 3 deiodinase Thyroid enlargement Increased iodine clearance Thyroid function test change Elevation of T4 and T3 Elevated FT4 and suppressed TSH Increased T4 and T3 pool size Potential increased T4 and T3 degradation Increased serum Tg Reduced hormone production in iodine insufficient Fetal Ontogeny and Physiology T3 dependent CNS development Thyroid organogenesis, iodine concentration and hormonogeneiss Dependence on maternal iodothyronines Thyroid Deficiency in the Fetus and Neonate 2 sources of thyroid hormones in fetus Fetal thyroid which begins synthesis at 10 – 12 weeks Maternal thyroid hormones -current evidence shows substantial transfer across the placenta -placenta contains deiodinase that converts T4 to T3 Thyroid Tests Thyroid Hormones – TT3,TT4, FT3, FT4 FT4I, TSH Thyroid antibodies TPOAb,TgAb, TSHRAb (TSI,TBII) Hyperthyroidism Etiologies Clinical presentations Diagnosis Maternal and fetal consequences Therapeutic options Hyperthyroidism Occurs in 1-2/1000 pregnancies Causes of hyperthyroidism in pregnancy Grave’s Disease Gestational Thyrotoxicosis Hydatidiform mole Silent Thyroiditis Multinodular toxic goiter Toxic adenoma Subacute thyroiditis Iatrogenic hyperthyroidism\Iodine induced hyperthyroidism Case 1 Leah a 25 year old G1P0 female was confined on her 10th week of gestation because of nausea and vomiting several times daily requiring parenteral fluids. She was referred to you for endocrine evaluation. 2 weeks earlier she was confined for the same problem and gastroscopy was done which was negative. Case 1 She has not had any weight gain since start of pregnancy. She had no history of thyroid problem. PE showed no goiter, no tremors nor eye signs. BP was normal. Pulse rate was 92/minute and was afebrile. Thyroid Function tests FT3 RIA 4.74 pmol/l (4.2-12) FT4 RIA 25 pmol/l (8.8-33) TSH IRMA 0.08 uIU/ml (0.35 – 5.0) Question What is your likely diagnosis? differential diagnosis? Conditions with suppressed TSH Increased thyroid hormone production Grave’s Disease Autonomous Thyroid nodule Hyperemesis gravidarum Molar Pregnancy First trimester pregnancy Conditions with Suppressed TSH • • • Normal or Low Thyroid Production Post therapy of hyperthyroidism Pituitary/hypothalamic disease Severe nonthyroidal illness Gestational Thyrotoxicosis Spectrum of hCG-induced hyperthyroidism which ranges from an isolated subnormal TSH concentration(up to 18%) to elevation of free thyroid hormone levels in the clinical setting of hyperemesis gravidarum Question 2 Will you treat? Treatment is not generally recommended. Is vomiting related to hyperthyroidism? Not likely Vomiting seen in hypothyroid, euthyroid and hyperthyroid, probably related to hCG induced elevation of estradiol Question 3 How will you follow up? Repeat thyroid function tests after 20th week If persistent hyperemesis and elevated thyroid hormones and suppressed TSH after 20 weeks of gestation consider antithyroid treatment as this may be mild Grave’s disease. Gestational Thyrotoxicosis Transient Symptoms usually resolve within 10 weeks of diagnosis Differs from Grave’s Non-autoimmune etiology (hCG induced) with negative anti thyroid and anti TSH receptor antibody Negative goiter Resolution in almost all patients after 20 weeks of gestation No ophthalmopathy Case 2 Luisa a 30 year old G2P1 female was referred to you on her 12th week of pregnancy because of hypertension, palpitations and weight loss of 5 lbs since start of pregnancy. BP was 145/95 despite bed rest. Cardiologist gave apresoline 10 mg tid. Urinalysis was negative for protein. Case 2 Prominent eyes were noted so endocrine referral was sought. Further history taking revealed hyperthyroidism 3 years ago with ATD treatment for 1 year. On PE, BP was 140/90 PR 110/minute, with positive lid retraction, diffuse goiter and bruit and fine hand tremors. No leg edema Thyroid tests FT3 RIA 15 pmol/l ( 4.2-12) FT4RIA 55 pmol/l (8.8 – 33) TSH-IRMA 0.002 uIU/L (0.355.0) Question 1 What is your likely diagnosis? Chronic hypertension Grave’s – eye signs, goiter, bruit Diagnosis of Grave’s Symptoms of hypermetabolic state Sometimes goiter with bruit Eye signs Elevated free T3 and freeT4 Suppressed TSH RAIU elevated(not done in pregnant) Elevated TgAb and TPOAb TSH-R Ab positive Grave’s Hyperthyroidism Positive thyroid antibodies TPOAb TgAb TSHRAb (TSI) Unusual to present for the first time in pregnancy Symptoms usually antedate pregnancy for a few months Question 2 What are other tests are useful to confirm your diagnosis if available? TPOAb TgAb TSHRAb/TSI – to differentiate from silent thyroiditis Question 3 What is your treatment of choice? Which ATD is best? PTU favored because: MMI has been associated with aplasia cutis a congenital scalp defect (Mandel 1994 Thyroid 4:129-133) PTU is heavily protein bound and believed to cross placenta less 6 women without history of thyroid disease received a single injection of either (35S)MMI or PTU in the first half of pregnancy prior to a therapeutic abortion (Marchant 1977 JCEM 45:1187-1193) Which ATD is best? an in vitro study showed two drugs equally passed placental barrier (Mortimer 1997 JCEM 82:3099) no prospective RCTs compared maternal and fetal outcome; retrospective case series have shown that the rate of fetal hypothyroidism is similar with both drugs (Wing 1994 Am J Obstet Gynecol 170:90) What is the dose of ATD in pregnant? Initial dose may vary according to severity of maternal hypothyroidism Use the lowest dose possible to maintain maternal euthyroidism 15-10 mg MMI or 300 mg PTU In 30% ATD may be discontinued in last trimester Effect of ATD overdose on fetus fetal goiter which may lead to respiratory distress Intrauterine growth retardation 4 studies showed no defects in either cognitive or somatic development of children exposed to maternal ATD in utero but maternal thyroid hormone levels not known PTU vs MMI Duration of action Potency Placental passage Breast milk Toxicity Other short less about 1 less blocks T4 to T3 long more prob 1 more aplasia cutis Question 4 What are your treatment goals? Guidelines for clinical management of maternal hyperthyroidism during pregnancy Use the lowest dose of ATDs to maintain maternal thyroid hormone levels in the upper 1/3 of the normal range to slightly elevated during pregnancy.(FT4 23-25 pmol/l or 1.8-2.0 ng/dl) Guidelines for clinical management of maternal hyperthyroidism during pregnancy Check maternal thyroid hormone levels monthly, using free T4 levels Measure TSI/TBII at 26-28 weeks Consider fetal ultrasound at 26-28 weeks if the TSI/TBII levels are elevated or if Doppler detects fetal tachycardia Other forms of treatment Beta adrenergic blockers –may be used transiently to control adrenergic symptoms ( small series where propranolol was prescribed for 6-12 weeks reported higher rates of miscarriages) Iodides should not be used but may be used if needed to prepare for thyroidectomy Surgery in latter half of second trimester Question 5 What are maternal and fetal consequences of hyperthyroidism? Pregnancy complications reported in hyperthyroid women Maternal pre-ecclampsia(14% if untreated vs 6%for treated) Gestational hypertension pregnancy-induced hypertension placental abruption Congestive heart failure(63% if untreated) Preterm labor(88% if untreated; 25% partial treatment 8% if adequate treatment) Other potential complications of uncontrolled hyperthyroidism Maternal Anemia Miscarriage Thyroid storm Fetal prematurity Pregnancy complications reported in hyperthyroid women Fetal Small for gestation age Intrauterine growth retardation Stillbirth (50% if untreated, 16% partial treatment) Fetal/neonatal hyperthyroidism Case 3 Marissa a 32 year old G5P2 Ab2 female was referred on her 8th weeks of pregnancy because of easy fatigability and hypertension. Her weight gain was 5 lbs in 8 weeks. Case 3 Patient had radioactive treatment 3 years ago for Grave’s disease and is on levthyroxine replacement 75 mcg/day. Last thyroid tests were 10 weeks ago and were normal. PE showed BP 145/95 Pulse rate was 70/minute no goiter, DTR were hypoactive. Thyroid tests FT3RIA 3.8 pmol/L (4.2 – 12) FT4 RIA 8.8 pmol/l (8.8 – 33) TSHIRMA 25 uIU/ml (0.35 – 5.0) Question 1 What is your diagnosis? Hypothyroidism in Pregnancy Hypertension Is this expected? Diagnosis of hypothyroidism Nonspecific signs fatigue Weight gain Constipation Edema TSH is first line screening test Thyroid hormone therapy during pregnancy Increased requirement during pregnancy By about 45% in one study (12 patients)Mandel et al NEJM 1990 By 67 ug/day in another study Appeared early in first trimester and throughout pregnancy Question 2 How will you adjust your dose? Treatment of hypothyroidism in pregnancy Initial dosage 150 mcg/day or 2 mcg/kg actual body weight Readjustment TSH high but <10mU/ml add 50 mcg/day TSH>10<20 add75mcg/day TSH>20 add 100 mcg/day guidelines for clinical management of maternal hypothyroidism Hashimoto’s thyroiditis – 25% increment Subclinical hypothyroidism may not require increment TSH should be monitored every 8-10 weeks or if a dose adjustment is made, should be checked 4 weeks later. 25% of those with initial normal serum TSH levels in the first trimester and 37% of those with initial normal serum TSH in second trimester will later require dosage increases Hypothyroidism Patients should be instructed to separate levothyroxine ingestion and prenatal vitamin containing iron or iron supplements by at least 6 hours After delivery, the levothyroxine dose should be reduced to prepregnancy dosage and the serum TSH level should be rechecked at 6 weeks postpartum Question 3 The patient asks you on possible consequences to baby What will you tell her? Complications in Pregnant Hypothyroidism Maternal Gestational hypertension- 22% in overt, 15% in subclinical,7.6% in general population Pre-ecclampsia Pregnancy induced hypertension Postpartum hemorrhage Anemia- 31% in overt, 0% in subclinical Placenta abruption 18% in overt, 0% in subclinical Maternal consequence of Hypothyroidism 25756 singleton pregnancies 2.3% had subclinical hypothyroidism Placental abruption occurred more often (RR 3.9, 95% CI 1.1-8.2 Preterm birth (<34 weeks) more common (RR 1.8, 95% CI 1.1 -2.9) Casey Obstetric Gynecol 2005;105:239-245 Complications In Pregnant Hypothyroidism Fetal Small for gestational age – 22% in overt, 9% in subclinical, 6-8% in general population Stillbirth – 56% in overt, 6% in subclinical Transient congenital hypothyroidism due to transplacental passage of maternal blocking antibodies Possible impairment in cognitive function Impaired somatic development Hypothyroidism in pregnancy 9403 singleton pregnancies TSH >6mU/L in 2% Fetal death OR 4.4 CI 1.9-9.5 Allan WC J Med Screening 2000;7:127 Consequence of hypothryoidism in pregnancy TSH measured in 25216 pregancnt women 47 women TSH >99.7th tile 15 with TSH 98-99th tile + low T4 124 matched women with normal TSH At 7-9 y/o had 15 test for intelligence, attention, language, reading abililty, school performance and visual motor performance Haddow NEJM 1999:341;549 Haddow study in 62 children born to women with TSH mean 13.4 vs 1.4 in control on 17th week of gestation FT4 0.7 vs 1 ng/dl Lower performance on all 15 tests, IQ average 4 points lower More had IQ <85 (15% vs 5%) Children of 48 mothers untreated for hypothyroidism had IQ average 7 points lower (p0.005) with 19 scoring <85 Haddow study Conclusions Decreased intellectual and school performance in children exposed to mild asymptomatic hypothyroidism intellectual and school performance was not affected if hypothyroidism was treated with thyroxine replacement even if not adequate Maternal thyroid peroxidase antibodies during pregnancy: a marker of impaired child development? Lower IQ in children of euthyroid mothers with elevated TPO-ab vs negative TPO ab titers Pop et al JCEM 1995 Screening Insufficient evidence to support population bases screening However aggressive case finding is appropriate in pregnant women Surks JAMA 2004;291:228 Case 4 Isabel a 40 year old G7P7 female was referred to you 3 months after delivery because of sluggishness and depression. Upon further history you elicited sore throat and neck pain accompanied by palpitations 1 month after delivery which lasted for 2 weeks. ENT consult was done and was given antibiotics. PE showed a diffuse non tender goiter, no cervical lymphadenopathy. Thyroid tests FT3 3.5 pmol/l FT4 18 pmol/l TSH 15 uIU/ml Question 1 What are your considerations? Postpartum thyroid disease Spectrum of autoimmune thyroid diseases Postpartum thyroid disease Subacute thyroiditis Hashimoto’s thyroiditis Grave’s (recurrence) Postpartum thyroiditis vs subacute (de Quervain’s) PPT painless TPOab high Tgab high ESR slightly high SAT painful neg or low neg or low very high Risks for postpartum thyroid disease High risk: Prior episode of PPTD History of Hashimoto’s or Grave’s disease Type 1 diabetes mellitus Recurrent miscarriages Moderate risk Goiter Family history of thyroid disease Three phases of PPTD Transient hyperthyroidism due to leakage of hormone low RAIU, not pain, ESR normal or slightly elevated lymphocytic thyroiditis 2-3months up to 6 months post partum Transient hypothyroidism euthyroidism Postpartum thyroiditis 8-10% of women Temporary period of hyperthyroidism of 6 weeks to 3 months postpartum No treatment for hyperthyroid phase but beta blockers may be used to relieve symptoms 6-12 months of LT4 in hypothyroid phase; some long term Subacute Thyroiditis Granulomatous type Painful RAIU – 0 ? viral Question 2 What other tests will you request? Diagnostic tests RAIU - 2hrs, 5% (NV = 5-12%) 24 hrs, 15% (NV =1545%) ESR - 23 mml/hr TGAb - 150 IU/ml (NV = 0 - 60) TPOAb - 1200 IU/ml (NV = 0-100) Question 3 How will you manage this patient? Treatment for PPTD Levothyroxine if hypothyroidism is symptomatic hypothyroidism may occur up to one year postpartum Persistent or new hypothyroidism occurs in about 25% after one year.. Summary Slide Thyroid disorders should be considered in pregnancy in patients at risk. Signs and symptoms may be misleading so there should be a high index of suspicion. Thyroid tests should be used and interpreted in the light of physiologic changes during pregnancy. Judicious treatment is critical to assure success in pregnancy outcome Thank You!